Takeaways from Our Management Team Call

Research evidence excerpt

Takeaways from Our Management Team Call

by elevated BTK and CD79C expression when

compared to PsO and elevated BTK, CD79B, JCHAIN, and immunoglobulins when compared

to AD. In addition, HS lesions also demonstrated clear dysregulation of Th17 responses where

compared with healthy controls, HS lesions were associated with elevated IL-17F and Th17-

associated IL-6 and IL-36G. Further, HS and PsO lesions shared dysregulated expression of

IL-17 signaling genes (IL-17F, CCL20, IL-23R, IL-12A, KLRB1, CCR7, CXCL1, and S100A8)

and HS lesions demonstrated unique dysregulation of IL-17F, IL-23R, and KLRB1 relative to AD

lesions. Altogether, this publication supports a clear role of both IL-17 and B cells in the immune

responses to HS, particularly in the context of severe disease. Thus, this paper adds additional

strong evidence for the mechanistic rationale for tibulizumab in HS further de-risking PoS for

TibuSHIELD with topline expected in 4Q26.

TibuSURE has already exceeded the initial n=80 target for recruitment with over-

enrollment to complete imminently in early July. Moreover, ZURA updated that tibulizumab's

24-week Ph2 TibuSURE (NCT06843239) has already exceeded recruitment beyond the initial

target of n=80 early diffuse SSc patients, and is on-track to over-enroll the study with completion

in ~early July. In fact, mgmt shared that over-enrollment completion will be done soon, with the

team finalizing the last few patient dynamics now to wrap up those processes and dose the

final patient for the study. When asked how many patients were over-enrolled in TibuSURE,

mgmt prefaced the final number is not yet determined, but it would not be enough to trigger

a protocol change. Rather, expect the final number recruitment to be in-line with the initial